Cabozantinib Pregnancy and Breastfeeding Warnings
Cabozantinib is also known as: Cometriq
Cabozantinib Pregnancy Warnings
Embryolethality was observed in animals at exposures below the recommended human dose. Increased loss of pregnancy (at less than 1% of the human exposure by AUC at the recommended dose), delayed ossifications and skeletal variations (at approximately 0.03% of the human exposure by AUC at the recommended dose), and visceral malformations and variations including reduced spleen size and missing lung lobe (at approximately 11% of the human exposure by AUC at the recommended dose) were seen in animal studies. Animal studies showed impairment of male and female fertility. A decrease in sperm counts and reproductive organ weights (at approximately equal to the human exposure by AUC at the recommended dose) and a significant decrease in the number of live embryos and a significant increase in pre- and postimplantation losses (at approximately 50% of the human exposure by AUC at the recommended dose) was observed. In addition, hypospermia and absence of corpora lutea at 6% and 3%, respectively, the human exposure by AUC at the recommended dose and ovarian necrosis equal to the human exposure by AUC at the recommended dose was seen in animals. There are no controlled data in human pregnancy. FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
FDA pregnancy category: D If used during pregnancy or if patient becomes pregnant, the patient should be warned of the potential hazards to the fetus. Comments: Females and males with female partners of childbearing age should use adequate methods of contraception during treatment and for at least 4 months after the last dose.
Cabozantinib Breastfeeding Warnings
A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Unknown The effects in the nursing infant are unknown.
- cabozantinib Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.